Pharmadrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen joined Proactive's Stephen Gunnion with details of the findings of a study of its cepharanthine (PD-001) candidate, which showed that when it is combined with chemotherapy drug paclitaxel it can treat esophageal cancer.
Cohen telling Proactive that the study showed cepharanthine to reduce tumor volume and improve the inhibition of tumor growth.
He said the study also further support PharmaDrug's goal of moving towards an FDA clinical trial and will provide the company with the opportunity to fully leverage the benefits of the previously granted FDA orphan drug designation for cepharanthine-based treatment of esophageal cancer.